View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
March 25, 2021

LoA Update: ReGenTree’s US approval chance for timbetasin in dry eye drops six points after Phase III miss

As of 19 March, the FDA likelihood of approval (LoA) for ReGenTree’s timbetasin acetate in dry eye disease dropped six points, according to GlobalData’s LoA data.

By Sean Rai-Roche

As of 19 March, the FDA likelihood of approval (LoA) for ReGenTree’s timbetasin acetate in dry eye disease dropped six points, according to GlobalData’s LoA data. The change is down to the company announcing that its Phase III ARISE-3 trial did not meet its primary outcome measures.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

While timbetasin acetate previously had a 28% LoA, this has fallen to 22% after the topline results using GlobalData’s analysis using a combination of machine learning and its proprietary algorithm. According to an 18 March press release, timbetasin acetate did not meet its primary outcome measure of reducing corneal staining 15 days after dosing or alleviating ocular discomfort.

ARISE-3 is a randomised, quadruple-masked, placebo-controlled trial to evaluate timbetasin acetate in 700 patients with a subject reported history of dry eye for at least six months. In the trial, timbetasin acetate, a sterile eye drop, was administered four times a day for 14 days.

Sean Rai-Roche is a Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena